Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer
This study has been completed.
Information provided by (Responsible Party):
First received: November 2, 2007
Last updated: August 6, 2014
Last verified: August 2014
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||July 2014|
|Primary Completion Date:||August 2010 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||November 15, 2011|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Park K, Cho BC, Kim DW, Ahn MJ, Lee SY, Gernhardt D, Taylor I, Campbell AK, Zhang H, Giri N, Letrent SP, O'Connell J, Heo DS. Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial. J Thorac Oncol. 2014 Oct;9(10):1523-31. doi: 10.1097/JTO.0000000000000275.